[
    "{\"step_by_step_thinking\": \"Based on the information provided in the relevant documents, Tisagenlecleucel is indicated for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The JULIET phase 2 trial, which evaluated the efficacy and safety of Tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas, showed a best overall response rate of 52% and a complete response rate of 40%. Therefore, the answer is A. yes, Tisagenlecleucel is effective for B-Cell Lymphoma.\", \"answer_choice\": \"A\"}"
]